SG10201801459SA - Compositions and methods for live, attenuated alphavirus formulations - Google Patents

Compositions and methods for live, attenuated alphavirus formulations

Info

Publication number
SG10201801459SA
SG10201801459SA SG10201801459SA SG10201801459SA SG10201801459SA SG 10201801459S A SG10201801459S A SG 10201801459SA SG 10201801459S A SG10201801459S A SG 10201801459SA SG 10201801459S A SG10201801459S A SG 10201801459SA SG 10201801459S A SG10201801459S A SG 10201801459SA
Authority
SG
Singapore
Prior art keywords
live
compositions
methods
attenuated alphavirus
formulations
Prior art date
Application number
SG10201801459SA
Other languages
English (en)
Inventor
Dan T Stinchcomb
Jill A Livengood
Laszlo Varga
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489420&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201801459S(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of SG10201801459SA publication Critical patent/SG10201801459SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG10201801459SA 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations SG10201801459SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361784122P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
SG10201801459SA true SG10201801459SA (en) 2018-03-28

Family

ID=50489420

Family Applications (3)

Application Number Title Priority Date Filing Date
SG11201507462QA SG11201507462QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201909051Q SG10201909051QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201801459SA SG10201801459SA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Family Applications Before (2)

Application Number Title Priority Date Filing Date
SG11201507462QA SG11201507462QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations
SG10201909051Q SG10201909051QA (en) 2013-03-14 2014-03-13 Compositions and methods for live, attenuated alphavirus formulations

Country Status (20)

Country Link
US (2) US10137186B2 (ja)
EP (2) EP2968515B1 (ja)
JP (3) JP6426695B2 (ja)
KR (1) KR20160003662A (ja)
CN (2) CN111729077A (ja)
AP (1) AP2015008733A0 (ja)
AU (2) AU2014236804B2 (ja)
BR (1) BR112015023205A2 (ja)
CA (1) CA2903711A1 (ja)
CR (1) CR20150553A (ja)
DO (1) DOP2015000226A (ja)
EC (1) ECSP20007842A (ja)
HK (1) HK1220358A1 (ja)
MX (2) MX361342B (ja)
MY (1) MY178476A (ja)
NZ (1) NZ631012A (ja)
PH (1) PH12015502115A1 (ja)
SG (3) SG11201507462QA (ja)
TW (2) TWI649087B (ja)
WO (1) WO2014151855A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2015008733A0 (en) 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations
WO2015097650A1 (en) 2013-12-23 2015-07-02 Theravectys Lyophilized lentiviral vector particles, compositions and methods
PE20190149A1 (es) * 2016-03-31 2019-01-22 Takeda Vaccines Inc Composiciones y metodos para estabilizar alfavirus con formulaciones mejoradas
NL2022538B1 (en) * 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
JPWO2022158097A1 (ja) * 2021-01-19 2022-07-28

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338335A (en) * 1980-02-05 1982-07-06 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
RU2035508C1 (ru) * 1991-08-16 1995-05-20 Институт органической химии СО РАН Питательная среда для стабилизации вируса венесуэльского энцефалита лошадей
US5545555A (en) * 1994-07-25 1996-08-13 Microtest, Inc. Microbial transport media
AU4594996A (en) * 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US6465634B1 (en) * 1996-04-05 2002-10-15 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
US6210683B1 (en) 1997-09-05 2001-04-03 Merck & Co., Inc. Stabilizers containing recombinant human serum albumin for live virus vaccines
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
AU5247199A (en) * 1998-07-30 2000-03-14 Johns Hopkins University School Of Medicine, The Targeted alphavirus and alphaviral vectors
US6869907B2 (en) * 2000-05-02 2005-03-22 Pentax Corporation Color-image-forming medium
FR2814957B1 (fr) 2000-10-06 2002-12-20 Aventis Pasteur Composition vaccinale et procede de stabilisation
WO2003049764A1 (en) * 2001-12-12 2003-06-19 Fh Faulding & Co Limited Composition for viral preservation
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
US8603796B2 (en) 2003-12-17 2013-12-10 Wyeth Llc Method for producing storage stable viruses and immunogenic compositions thereof
US8865184B2 (en) * 2006-09-01 2014-10-21 Bharat Biotech International Limited Vaccine for chikungunya virus infection
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
TWI417113B (zh) 2006-11-07 2013-12-01 Acambis Inc 以凍乾法穩定疫苗
KR20170038110A (ko) 2007-04-06 2017-04-05 다케다 백신즈 인코포레이티드 살아있는 약독화된 바이러스를 위한 방법 및 조성물
US8357525B2 (en) 2007-09-04 2013-01-22 The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention Thermal inactivation of rotavirus
PL2198007T3 (pl) 2007-09-14 2018-03-30 Sanofi Pasteur Biologics, Llc Kompozycje farmaceutyczne zawierające toksoidy A i B Clostridium difficile
KR101913790B1 (ko) 2008-01-24 2018-12-28 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모기에서 복제 불가능한 약독화된 재조합 알파바이러스 및 그의 용도
DK2759306T3 (en) 2008-12-09 2016-05-09 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US20130028933A1 (en) 2009-12-28 2013-01-31 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
NZ603863A (en) 2010-06-01 2014-09-26 Novartis Ag Concentration and lyophilization of influenza vaccine antigens
AP2015008733A0 (en) * 2013-03-14 2015-09-30 Takeda Vaccines Inc Compositions and methods for live, attenuated alphavirus formulations

Also Published As

Publication number Publication date
JP2020193231A (ja) 2020-12-03
HK1220358A1 (zh) 2017-05-05
TW201900192A (zh) 2019-01-01
US10806781B2 (en) 2020-10-20
AU2018236897B2 (en) 2020-09-10
JP6426695B2 (ja) 2018-11-21
US20140271715A1 (en) 2014-09-18
CA2903711A1 (en) 2014-09-25
SG10201909051QA (en) 2019-11-28
JP6761015B2 (ja) 2020-09-23
ECSP20007842A (es) 2020-09-30
MX2015012894A (es) 2016-04-04
US10137186B2 (en) 2018-11-27
DOP2015000226A (es) 2016-02-29
CN111729077A (zh) 2020-10-02
JP2019031543A (ja) 2019-02-28
EP2968515B1 (en) 2019-05-08
TWI649087B (zh) 2019-02-01
AP2015008733A0 (en) 2015-09-30
EP2968515A1 (en) 2016-01-20
CN105377293A (zh) 2016-03-02
EP3603667A1 (en) 2020-02-05
NZ631012A (en) 2017-08-25
MX361342B (es) 2018-12-04
PH12015502115B1 (en) 2016-01-25
MX2018014977A (es) 2022-06-27
BR112015023205A2 (pt) 2017-07-18
CR20150553A (es) 2015-12-01
TW201513875A (zh) 2015-04-16
WO2014151855A1 (en) 2014-09-25
CN105377293B (zh) 2020-07-17
KR20160003662A (ko) 2016-01-11
SG11201507462QA (en) 2015-10-29
AU2014236804B2 (en) 2018-12-13
MY178476A (en) 2020-10-14
PH12015502115A1 (en) 2016-01-25
US20190134182A1 (en) 2019-05-09
AU2018236897A1 (en) 2018-10-18
JP2016513658A (ja) 2016-05-16
AU2014236804A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
IL273205A (en) Preparations and methods
HK1225650A1 (zh) 用於提高萊鮑迪苷m溶解度的組合物和方法
HK1218837A1 (zh) 組合物和方法
HK1218560A1 (zh) 組成與方法
GB2527241B (en) Compositions and methods
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
GB201319791D0 (en) Formulations
ZA201505390B (en) Compositions and methods for treating pests
GB201308072D0 (en) Compositions and methods
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
SG11201506605XA (en) Ion implantation compositions, systems, and methods
HK1213800A1 (zh) 類毒素、組合物及相關方法
EP2981529A4 (en) ORIDONIN ANALOGUES, COMPOSITIONS AND RELATED METHODS
IL266767A (en) Compounds, compositions and methods for making dihydroxyphenyl neurotransmitter
EP2953455A4 (en) ANTIMICROBIAL COMPOSITIONS, WIPES AND METHODS
GB201305813D0 (en) Compositions and methods
IL242795B (en) Preparations, methods and devices for dialysis
IL243778A0 (en) Combined immune complexes
HK1214951A1 (zh) 眼用製劑
HK1220358A1 (zh) 減毒活甲病毒製劑的組合物和方法
HUE037525T2 (hu) Kis sejtmagvacska RNS (SNORNA), készítmények és alkalmazások
HK1213917A1 (zh) 類霉素、組合物及相關方法
HK1212916A1 (zh) 包含炮製提取物的組合物
EP3102557A4 (en) Improved compositions and methods comprising resveratrol
GB201313990D0 (en) Combination immunogenic compositions